Evidence map›Paper›PMID 39591649›Full record

ArticleThe American journal of tropical medicine and hygiene2025

Optimizing the Use of SARS-CoV-2 Antigen Rapid Diagnostic Tests for the Timely Detection of and Response to COVID-19 in Schools and Markets in Uganda.

Jerry Mulondo, Susan Nayiga, Winnie Nuwagaba, Patience Nayebare, Jane Frances Namuganga, Isaac Ssewanyana, Moses R Kamya, Joaniter I Nankabirwa

Abstract read
In one paragraph

Article in The American journal of tropical medicine and hygiene, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jerry MulondoInfectious Diseases Research Collaboration, Kampala, Uganda.
Susan NayigaInfectious Diseases Research Collaboration, Kampala, Uganda.
Winnie NuwagabaInfectious Diseases Research Collaboration, Kampala, Uganda.
Patience NayebareInfectious Diseases Research Collaboration, Kampala, Uganda.
Jane Frances NamugangaInfectious Diseases Research Collaboration, Kampala, Uganda.
Isaac SsewanyanaInfectious Diseases Research Collaboration, Kampala, Uganda.
Moses R KamyaInfectious Diseases Research Collaboration, Kampala, Uganda.
Joaniter I NankabirwaInfectious Diseases Research Collaboration, Kampala, Uganda.

Funding

Training in malaria surveillance, epidemiology and implementation science research to strengthen malaria policy and control in UgandaD43TW010526 · FIC · MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES · PI MATTHEW G DORSEY, MOSES Robert KAMYA · 2017 to 2026
$2.3M
Impact of malaria control interventions on the infectious reservoir, host immunity, and drug resistance in UgandaK43TW010365 · FIC · INFECTIOUS DISEASES RES COLLABORATION · PI NANKABIRWA, JOANITER IMMACULATE · 2017 to 2021
$514k
FIC NIH HHS D43 TW010526FIC NIH HHS K43 TW010365
6 · The paper itself

Abstract

The early detection and management of infections is crucial to control epidemics. We evaluated the feasibility and utility of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen rapid diagnostic tests (Ag-RDTs) for the timely detection of and response to coronavirus disease 2019 in high-risk border communities in Uganda. Between May and September 2022, monthly cross-sectional surveys were conducted in 11 schools and two markets in two border districts. Only baseline and end-line testing were also performed in matched control communities. Antigen rapid diagnostic test results and demographic and clinical data were collected, and contacts of patients were traced and tested. All patients were advised to self-isolate, and compliance was assessed on day 5. We enrolled 10,406 participants out of 10,472 screened individuals. The participants had a 1.3% test positivity rate, with schools recording higher, but non-significant, positivity rates than markets (1.4% versus 0.9%; P = 0.149). We tracked 556 contacts, and 536 (96.4%) agreed to test. The test positivity rate was significantly higher among contacts than the index participants (8.8% versus 1.3%; P <0.001). Only 55 (29.7%) of the index participants self-isolated effectively. Settings that received monthly testing had lower end-line positivity rates than controls (0.3% versus 1.4%; P = 0.001). Repeated SARS-CoV-2 Ag-RDT testing is feasible and could reduce SARS-CoV-2 infections. However, the participation in testing may have been enhanced by the compensation provided. Also, isolation was limited, which may reduce the impact of the intervention when rolled out on a large scale. Innovative strategies to increase the isolation of patients could improve the utility of early testing for transmission reduction during epidemics.

Indexed as

Antigens, ViralCOVID-19COVID-19 Serological TestingSARS-CoV-2AdolescentAdultChildChild, PreschoolCOVID-19 TestingCross-Sectional StudiesFemaleHumansMaleMiddle AgedRapid Diagnostic TestsSchoolsAntigens, Viral

Identifiers

PMID39591649
PMCPMC11965717

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.